Neuromuscular Depolarizing Agents

Drugs that interrupt transmission at the skeletal neuromuscular junction by causing sustained depolarization of the motor end plate. These agents are primarily used as adjuvants in surgical anesthesia to cause skeletal muscle relaxation.

Also Known As:

Networked: 80 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Rueffert, H: 3 articles (11/2009 - 08/2002)
2.	Wehner, M: 3 articles (11/2009 - 08/2002)
3.	Olthoff, D: 3 articles (01/2003 - 02/2000)
4.	Miyoshi, Hirotsugu: 2 articles (01/2022 - 10/2015)
5.	Mukaida, Keiko: 2 articles (01/2022 - 10/2015)
6.	Nakamura, Ryuji: 2 articles (01/2022 - 10/2015)
7.	Otsuki, Sachiko: 2 articles (01/2022 - 10/2015)
8.	Yasuda, Toshimichi: 2 articles (01/2022 - 10/2015)
9.	Stowell, Kathryn M: 2 articles (01/2019 - 11/2008)
10.	Treves, S: 2 articles (07/2015 - 10/2001)

Related Diseases

1.	Neuromuscular Diseases (Neuromuscular Disease) 06/01/1975 - "Decamethonium and succinylcholine were used to study the effects of depolarizing muscle relaxants on serum potassium in 60 patinets, free of neuromuscular disease, during major orthopedic surgery. "
2.	Malignant Hyperthermia 01/01/2019 - "Malignant hyperthermia (MH) is an uncommon, autosomal dominant disorder of skeletal muscle, triggered by inhalational anaesthetics or depolarizing muscle relaxants. " 06/01/2008 - "Malignant hyperthermia is a rare, potentially life threatening pharmacogenetic disorder triggered by volatile anaesthetics and depolarizing muscle relaxants. " 09/15/2003 - "Malignant hyperthermia is an autosomal dominant disorder of the skeletal muscle that predisposes affected individuals to a life-threatening hypermetabolic reaction in response to volatile anaesthetics and depolarizing muscle relaxants. " 08/01/2002 - "Malignant hyperthermia (MH) is an autosomal-dominant disorder of skeletal muscle, triggered by volatile anaesthetics and depolarizing muscle relaxants. " 10/01/2001 - "Malignant hyperthermia is an autosomal-dominant inherited disorder of the skeletal muscle cell characterized by a hypermetabolic response to all commonly used inhalational anaesthetics and depolarizing muscle relaxants. "
3.	Rhabdomyolysis 07/01/2017 - "Additionally, they are at risk of developing malignant hyperthermia, rhabdomyolysis and hyperkalemic cardiac arrest when exposed to halogenated inhalational anaesthetics and depolarizing muscle relaxants. " 03/01/2005 - "Adverse reactions to volatile anesthetics and depolarizing muscle relaxants can occur in patients with Duchenne muscular dystrophy (DMD) resulting in acute rhabdomyolysis and hyperkalemia. " 10/16/2021 - "Patients with Becker muscular dystrophy (BMD) have a high risk of developing hyperkalemia, rhabdomyolysis, and malignant hyperthermia when exposed to volatile anesthetics and depolarizing muscle relaxants. " 01/01/2003 - "Malignant hyperthermia (MH) is a potentially lethal pharmacogenetic predisposition associated with a susceptibility to volatile anesthetics and depolarizing muscle relaxants that lead to a fulminant anesthetic crisis with hyperthermia, skeletal muscle rigidity, respiratory and metabolic acidosis, and muscle rhabdomyolysis. "
4.	Muscular Diseases (Myopathy) 01/01/2022 - "Malignant hyperthermia (MH) is an inherited muscle disorder induced by volatile anesthetics and depolarizing muscle relaxants. " 07/01/2015 - "Malignant hyperthermia (MH) is a potentially fatal pharmacogenetic myopathy triggered by exposure to volatile anesthetics and/or depolarizing muscle relaxants. " 09/23/2013 - "Malignant hyperthermia (MH), a metabolic myopathy triggered by volatile anesthetics and depolarizing muscle relaxants, is a potentially lethal complication of general anesthesia in susceptible patients. " 10/01/1999 - "Malignant Hyperthermia (MH) represents a functional myopathy triggered by volatile anesthetics and depolarizing muscle relaxants, and leading to metabolic disturbances of intracellular Calcium homeostasis. "
5.	Hyperkalemia 11/01/1996 - "Depolarizing muscle relaxants have not been used because of a significantly increased risk of hyperkalemia. " 03/01/2005 - "Adverse reactions to volatile anesthetics and depolarizing muscle relaxants can occur in patients with Duchenne muscular dystrophy (DMD) resulting in acute rhabdomyolysis and hyperkalemia. " 01/01/1994 - "The goal of anesthetic management is to prevent the known triggers of myotonic crisis, such as hypothermia, shivering, and hyperkalemia; and to avoid depolarizing muscle relaxants and anticholinesterase agents. " 10/16/2021 - "Patients with Becker muscular dystrophy (BMD) have a high risk of developing hyperkalemia, rhabdomyolysis, and malignant hyperthermia when exposed to volatile anesthetics and depolarizing muscle relaxants. "

Related Drugs and Biologics

1.	Succinylcholine (Suxamethonium Chloride)
2.	Potassium
3.	decamethonium (decamethonium bromide)
4.	Anesthetics (Anesthetic Agents)
5.	Calcium
6.	Inhalation Anesthetics
7.	Propofol (Diprivan)
8.	Neuromuscular Nondepolarizing Agents
9.	Anti-Bacterial Agents (Antibiotics)
10.	General Anesthetics

Related Therapies and Procedures

1.	Orthopedic Procedures
2.	General Anesthesia
3.	Cesarean Section (Caesarean Section)
4.	Intravenous Anesthesia
5.	Endotracheal Anesthesia